Table 1.

Met, PI3K, and mTORC1 inhibition in cancer therapy.

Compound	Targets	Status
Crizotinib	MET, ALK, ROS1, RON	Approved
Cabozantinib	VEGFR2, MET, RET, KIT, FLTs, TIE2, AXL	Approved
Capmatinib	MET	Phase II
Copanlisib	Pan-class I PI3K	Approved
Idelalisib	p110 delta	Approved
Taselisib	p110 alpha, delta and gamma	Phase III
Sirolimus	mTORC1	Approved
Everolimus	mTORC1	Approved
Temsirolimus	mTORC1	Approved